Sorafenib for Patients with Hepatocellular Carcinoma and Child‐Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study

LESSONS LEARNED: Recruitment of patients with advanced hepatocellular carcinoma and Child‐Pugh B for sorafenib treatment and additional pharmacokinetic studies is challenging. Patients with Child‐Pugh B liver cirrhosis have high rates of cirrhosis‐related adverse events. BACKGROUND: Few data are ava...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Labeur, Tim A., Achterbergh, Roos, Takkenberg, Bart, Van Delden, Otto, Mathôt, Ron, Klümpen, Heinz‐Josef
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Clinical Trial Results
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485346/
https://ncbi.nlm.nih.gov/pubmed/31645371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0718
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items